Wockhardt Stock Surges 19% Amid FDA Approval for Novel Antibiotic Wockhardt's stock price surged 19% on Monday, hitting an all-time high of ₹2,420 on the BSE, following the company's announcement of U.S. Food and Drug Administration (FDA) approval for Zaynich, a novel intravenous antibiotic. The stock also rallied 75% over the past month, outperforming the BSE Sensex's 3% decline. The approval, which came after a significant rise in trading volumes, marks a pivotal moment for the pharmaceutical company, positioning it as a leader in the fight against antimicrobial resistance. Zaynich, a combination of cefepime and zidebactam, is designed to treat complicated urinary tract infections (cUTIs), including pyelonephritis, in adults. The drug targets a critical market, as over 2.8 million antimicrobial-resistant infections occur annually in the U.S., causing more than 35,000 deaths. cUTIs alone account for over 600,000 hospitalizations each year, underscoring the drug's potential to address a significant unmet medical need. The FDA's approval is expected to unlock a $9 billion market opportunity in the U.S. alone, with ICICI Securities highlighting its transformative impact on Wockhardt's profitability. The approval of Zaynich is particularly notable as it represents the first new chemical entity (NCE) fully developed and commercialized by an Indian pharmaceutical company to receive U.S. FDA approval. Wockhardt's pipeline includes six antibiotics in various stages of development, with three targeting Gram-Negative pathogens and three targeting Gram-Positive bacteria. All six drugs have been granted Qualified Infectious Disease Product (QIDP) designation by the FDA, accelerating their development and enhancing their commercial prospects. Wockhardt's financial performance has also strengthened, with the company reporting a 12.#fda #icici_securities #ockhardt #zaynich #icra
